Financial Performance - The company's operating revenue for 2023 was CNY 226,999,688.91, a decrease of 12.25% compared to the previous year[5] - Net profit attributable to shareholders was CNY 51,224,844.16, down 9.24% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 34,891,112.81, a decline of 32.14% compared to the previous year[5] - Basic earnings per share decreased to CNY 1.34, down 28.72% year-on-year[5] Assets and Equity - Total assets at the end of the reporting period were CNY 535,502,865.11, an increase of 40.66% from the beginning of the period[5] - Shareholders' equity attributable to the company increased by 48.32% to CNY 458,339,701.92[5] - The company's capital stock increased by 33.69% to CNY 40,157,500.00[5] Market Conditions - The decline in revenue was primarily due to intensified domestic competition and reduced demand, leading to a decrease in sales of antiviral products by over CNY 13 million[6] Government Support - The company received government listing subsidies of CNY 12 million during the reporting period[6] Capital Increase - The increase in shareholders' equity and capital stock was mainly due to the company's listing on the Beijing Stock Exchange and the influx of raised funds[6]
峆一药业(430478) - 2023 Q4 - 年度业绩